Evidence map›Paper›PMID 42306238›Full record

ArticlePulmonary circulation2026

A Phase 2 Study of the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Patients With Pulmonary Hypertension Associated With Interstitial Lung Disease.

Colin Church, Maria Molina-Molina, Miguel Arias-Guillén, Patrick Muchmore, Ben R Lavon, Jan De Backer, Natalya Makulova, Bipin Mistry, Jia Guo, Jasmanda Wu and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary circulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05176951 (A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05176951 phase2completednot on this map

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease

TypeinterventionalSponsorInsmed IncorporatedRan2022 to 2024Enrolled39ConditionsPulmonary HypertensionArmsTreprostinil Palmitil, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Colin ChurchGolden Jubilee National University Hospital and University of Glasgow Glasgow UK.
Maria Molina-MolinaInterstitial Lung Disease Unit, Respiratory Department, Research Lab 4126, IDIBELL, UB University Hospital of Bellvitge Barcelona Spain.
Miguel Arias-GuillénRespiratory Department, Central University Hospital of Asturias University of Oviedo School of Medicine, ISPA; CIBERES (ISCIII) Oviedo Spain.
Patrick MuchmoreFLUIDDA, Inc. New York New York USA.
Ben R LavonFLUIDDA, Inc. New York New York USA.
Jan De BackerFLUIDDA, Inc. New York New York USA.
Natalya MakulovaInsmed Incorporated, Bridgewater New Jersey USA.
Bipin MistryInsmed Incorporated, Bridgewater New Jersey USA.
Jia GuoInsmed Incorporated, Bridgewater New Jersey USA.
Jasmanda WuInsmed Incorporated, Bridgewater New Jersey USA.
Junaideen FahumyInsmed Incorporated, Bridgewater New Jersey USA.
Ariel TeperInsmed Incorporated, Bridgewater New Jersey USA.
Peng-Liang ZhaoInsmed Incorporated, Bridgewater New Jersey USA.
Kevin C MangeInsmed Incorporated, Bridgewater New Jersey USA.
Gerald O'BrienInsmed Incorporated, Bridgewater New Jersey USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treprostinil palmitil (TP) inhalation powder (TPIP), an investigational formulation of the treprostinil prodrug TP, was designed to provide prolonged pulmonary vasodilation with once-daily administration. In this phase 2 study (NCT05176951), adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD) were randomized 3:1 to receive TPIP (

Indexed as

phase 2PH‐ILDpulmonary vasodilatorsTPIP

Identifiers

PMID42306238
PMCPMC13267426

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.